Trials / Unknown
UnknownNCT01802996
Evaluate the Efficacy of Magnesium Isoglycyrrhizinate in the Prevention of Chemotherapy Related Acute Liver Injury
A Randomized, Controlled, Multi-center Collaborative Study to Evaluate the Efficacy of Magnesium Isoglycyrrhizinate Injection in the Prevention of Antineoplastic Chemotherapy Related Acute Liver Injury
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 2,040 (estimated)
- Sponsor
- Cttq · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This purpose of this study is to evaluate the evaluate the efficacy of Magnesium Isoglycyrrhizinate Injection in the prevention of antineoplastic chemotherapy related acute liver injury.
Detailed description
Total subjects: 2040, experimental group of 1360 patients, control group of 680 patients. According to the study subjects receiving antineoplastic chemotherapy, subjects are stratified randomize.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Magnesium Isoglycyrrhizinate Injection | 200mg IV on day 1-5 |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2014-08-01
- Completion
- 2014-08-01
- First posted
- 2013-03-04
- Last updated
- 2013-10-30
Locations
27 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01802996. Inclusion in this directory is not an endorsement.